Best Prefered Companies To Invest In 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Coeur Mining (NYSE: CDE  ) were looking stronger today, gaining as much as 10% after announcing that it increased its investment in International Northair Mines.

So what: Coeur will nearly double its stake in Northair, adding 9,600,000 common shares to bring its total to 20,350,000 or 19.4% of the company. The agreement was part of a private placement, and Coeur agreed to a purchase price of $0.14 for the stock, which rose to $0.18 by midday. However, the total market cap of Northair is just $16 million, making that gain insignificant.

Now what: The new investment gives Coeur an increased stake in an exploration-stage miner currently focused on Northern Mexico. It's hard to say whether this investment will bear fruit in the near future, but it gives the company an additional potential revenue stream. Coeur also recently noted that production improved this quarter as silver extraction jumped 21% and gold production 7% as the miner's stock seems to be bouncing back from a four-year low it hit two weeks ago. Coeur will report quarterly earnings August 8 with analysts expecting a profit of $0.06 a share.

Best China Companies To Own For 2015: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors' Opinion:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

Best Prefered Companies To Invest In 2014: USEC Inc (USU)

USEC Inc. (USEC) is a global energy company, is a supplier of low enriched uranium (LEU) for commercial nuclear power plants. The Company operates in two segments: the low enriched uranium (LEU) segment with two components, separative work units (SWU) and uranium, and the contract services segment. The LEU segment is its primary business focus and includes sales of the SWU component of LEU, sales of both SWU and uranium components of LEU, and sales of uranium. The contract services segment includes work performed for Department of Energy (DOE) and its contractors at Portsmouth and Paducah, as well as nuclear energy services and technologies provided by NAC International Inc. (NAC). The Company supply LEU to both domestic and international utilities for use in about 150 nuclear reactors worldwide. The Company enriches uranium at the Paducah gaseous diffusion plant (GDP) that it leases from the United States DOE.

The Company is deploying advanced uranium enrichment technology, known as the American Centrifuge. USEC provide transportation and storage systems for spent nuclear fuel and provide nuclear and energy consulting services. It also performs contract work for DOE and its contractors at the Paducah and Portsmouth sites.

Low Enriched Uranium

The majority of the Company's customers are domestic and international utilities that operate nuclear power plants. During the year ended December 31, 2011, LEU segment�� international sales constituting 23% of revenue. Its agreements with electric utilities are primarily long-term, fixed-commitment contracts under which the Company's customers are obligated to purchase a specified quantity of SWU from the Company or long-term requirements contracts under which its customers are obligated to purchase a percentage of their SWU requirements from the Company.

Contract Services

The Company performs and earns revenue from contracts work through its subsidiary NAC and from contract work for DOE and DOE! contractors at the Paducah GDP and the site of the former Portsmouth GDP in Piketon, Ohio. NAC provides nuclear energy services and technologies, specializing in design, fabrication and implementation of spent nuclear fuel technologies including the high capacity MAGNASTOR system; nuclear materials transportation, and nuclear fuel cycle consulting services.

The Company competes with Urenco, Areva, State Atomic Energy Corporation and GE Hitachi Global Laser Enrichment (GLE).

Advisors' Opinion:

• [By John Udovich]

  Since the start of the week, small cap nuclear fuel stock USEC Inc (NYSE: USU) more than doubled for investors, something that has not happened for investors in uranium stocks like Uranium Resources, Inc (NASDAQ: URRE), Denison Mines Corp (NYSEMKT: DNN), Ur-Energy Inc. (NYSEMKT: URG) and Uranerz Energy Corp (NYSEMKT: URZ). To recap: USEC Inc closed at the $6 level on Friday, but then it surged to the $15 level on Monday only to open at the $10 level on Tuesday when it ultimately closed at $12.46. So what in the world is going on with USEC Inc and is it time to revisit nuclear fuel and uranium stocks?

• [By Paul Ausick]

  Stocks on the Move: Chegg Inc. (NYSE: CHGG) is down 21.8% at $9.77 after the company�� IPO today. USEC Inc. (NYSE: USU) is up 57.2% at $XX after the U.S. left duties in place on imports of French low-enriched uranium. James River Coal Co. (NASDAQ: JRCC) is up 19.5% at $1.41.

Best Prefered Companies To Invest In 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Grace L. Williams]

  Sarepta Therapeutics (SRPT) saw its director Anthony Chase buy 10,000 shares for $385,000. Sarepta saw a slight uptick in share price around this time after it announced positive results in a Phase 2b extension study involving the use of eteplirsen as a treatment for patients with Duchenne muscular dystrophy.

• [By Brian Orelli]

  After Sarepta Therapeutics (NASDAQ: SRPT  ) announced that it was going to have a conference call today to update investors about its plans for a marketing application with the Food and Drug Administration, I joked on Twitter that the lede for my article, "I couldn't have predicted this," worked either way.

Best Prefered Companies To Invest In 2014: Builders FirstSource Inc.(BLDR)

Builders FirstSource, Inc. engages in the manufacture and supply of structural and related building products for residential new construction primarily in the southern and eastern United States. The company offers prefabricated components, including floor trusses, roof trusses, wall panels, stairs, and engineered wood; and window and door products, such as aluminum and vinyl windows, and pre-hung interior and exterior doors, as well as assembles and distributes interior and exterior door units. It also provides lumber and lumber sheet products comprising dimensional lumber, plywood, and oriented strand board products; millwork products, including interior trim, exterior trim, columns, and posts, as well as custom exterior featured products; and other building products, such as cabinets, gypsum, hardware, composite materials, roofing, and insulation. In addition, the company offers turn-key framing, shell construction, design assistance, and professional installation servic es for products spanning its product categories, as well as provides a range of construction services. It serves customers ranging from production homebuilders to small custom homebuilders. The company was formerly known as BSL Holdings, Inc. and changed its name to Builders FirstSource, Inc. in October 1999. Builders FirstSource, Inc. was founded in 1998 and is based in Dallas, Texas.

Advisors' Opinion:

• [By Rex Moore]

  The annual Value Investor Conference is one of the premier events surrounding Berkshire Hathaway's annual meeting in Omaha. The Motley Fool's Michael Olsen and Rex Moore were in attendance and talked to several value investors.�In today's video, Michael asks Bob Robotti, founder of Robotti & Co., about his investment in Builders FirstSource (NASDAQ: BLDR  ) .

Best Prefered Companies To Invest In 2014: Renegade Petroleum Ltd (RPL)

Renegade Petroleum Ltd. (Renegade) is an exploitation and exploration focused light oil producer. Renegade's primary focus areas are located in southeast Saskatchewan in various pools, such as Bakken, Souris Valley, Frobisher, Midale and Kisby, as well as the Dodsland area of the Viking play in west-central Saskatchewan. It also has working interests in North Dakota pursuant to a farm-in agreement respecting land in Renville County that is prospective for Bakken, Threeforks/Sanish and Frobisher light oil. In addition the Company has a light oil opportunity in the Spearfish play in Manitoba. It has two geographic segments: western Canada and the State of North Dakota, the United Sates. In December 2012, the Company acquired certain strategic light oil assets. In February 2014, the Company closed the disposition of certain oil and gas assets in southeast Saskatchewan. Advisors' Opinion:

• [By John Udovich]

  Many American oil and gas investors are probably familiar with the major large and small cap players in the Bakken formation in North Dakota and Montana, but few American investors are probably familiar with�the active players further to the north in the�oil and gas rich Canadian provinces of Saskatchewan and Alberta�with small cap stocks like Alexander Energy Ltd (CVE: ALX), Renegade Petroleum Ltd (CVE: RPL) and Centor Energy Inc (OTCBB: CNTO) along with large cap Suncor Energy Inc (NYSE: SU) being among those�pumping out their share of noteworthy news lately. I should point out that�Canada�� oil reserves are ranked #3 after to Venezuela and Saudi Arabia with over 95% of these reserves being the controversial�oil sands of Alberta while the neighboring province of Saskatchewan (which the Bakken formation actually stretches into) along with offshore areas of Newfoundland also containing substantial production and reserves. Moreover and excluding the oil sands, Alberta would have 39% of Canada�� remaining conventional oil reserves,�followed by�offshore Newfoundland with�28% and Saskatchewan with 27%.